Patología Molecular de las enfermedades raras
PatMol-ER
Hospital Universitario San Juan de Alicante
San Juan de Alicante, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario San Juan de Alicante (80)
2025
2024
-
Applicability of the Zwolle score for selection of very high-risk ST-elevation myocardial infarction patients treated with primary angioplasty
Angiology, Vol. 75, Núm. 2, pp. 175-181
-
The CNIC-polypill (acetylsalicylic acid, atorvastatin, and ramipril), an effective and cost-saving secondary prevention strategy compared with other therapeutic options in patients with ischaemic heart disease
European Heart Journal Open, Vol. 4, Núm. 2
2023
-
Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial
International Journal of Cardiology, Vol. 391
-
Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase
Primary Care Diabetes, Vol. 17, Núm. 4, pp. 366-372
-
Differential prognosis of patients that are candidates for standard, short or prolonged dual antiplatelet treatment discharged after an acute coronary syndrome
Thrombosis Research, Vol. 224, pp. 46-51
-
Effect of dapagliflozin on COVID-19 infection and risk of hospitalization
The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2335-2342
-
Remnant cholesterol in patients admitted for acute coronary syndromes
European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 340-348
-
The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events
Journal of Clinical Lipidology, Vol. 17, Núm. 5, pp. 602-611
2022
-
Clinical and therapeutic characterization of the ischemic cardiopathy in Spain. Importance of cardiac rehabilitation programs
Medicina Clinica Practica, Vol. 5, Núm. 3
-
Early angiography in elderly patients with non-ST-segment elevation acute coronary syndrome: The cardio CHUS-HUSJ registry
International Journal of Cardiology, Vol. 351, pp. 8-14
-
Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry
European Journal of Clinical Investigation, Vol. 52, Núm. 12
-
Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors
Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 245-252
-
Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril-Valsartan in Clinical Trials
American journal of therapeutics, Vol. 29, Núm. 5, pp. e572-e575
-
Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry
Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529
-
Should PRECISE-DAPT be included for long-term prognostic stratification of diabetic patients with NSTEACS?
Acta Diabetologica, Vol. 59, Núm. 2, pp. 163-170
-
The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study
International Journal of Cardiology, Vol. 361, pp. 116-123
2021
-
Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events
Journal of cardiovascular pharmacology, Vol. 77, Núm. 2, pp. 164-169
-
Lipid lowering treatment in patients with very high risk cardiovascular disease. Spanish Society of Cardiology Consensus Document for the use of PCSK9 inhibitors in clinical practice
REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48
-
Long term prognostic benefit of complete revascularization in elderly presenting with NSTEMI: Real world evidence
Reviews in Cardiovascular Medicine, Vol. 22, Núm. 2, pp. 475-482